Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debashis Sarker

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
BMC Cancer|August 30, 2019
Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort studySam Sollie, Dominique S Michaud, Debashis Sarker, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 27, 2021
Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I studyKaushal Kundalia, Abdul Hakeem, Michail Papoulas, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Endocrine-Related Cancer|July 15, 2016
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumoursAlexa Childs, Amy Kirkwood, Julien Edeline, et al.
British Journal of Cancer|June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer, Divyanshu Dua, Nicola Cresti, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerDebashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
BMC Cancer|August 30, 2019
Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort studySam Sollie, Dominique S Michaud, Debashis Sarker, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 27, 2021
Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I studyKaushal Kundalia, Abdul Hakeem, Michail Papoulas, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Endocrine-Related Cancer|July 15, 2016
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumoursAlexa Childs, Amy Kirkwood, Julien Edeline, et al.
British Journal of Cancer|June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictorRuth Plummer, Divyanshu Dua, Nicola Cresti, et al.
British Journal of Cancer|April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2022
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced CancerRobert Jones, Ruth Plummer, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2021
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerDebashis Sarker, Nancy A Dawson, Ana M Aparicio, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Pageof 8